Colorectal cancer (CRC) screening reduces cancer-specific mortality and is widely recommended by international agencies. The fecal immunochemical test (FIT) is the preferred strategy for population-based screening. Although FIT-based screening is considered cost-effective internationally, no local evidence is available, and implementing such a program may require substantial resources. This study evaluated the cost-effectiveness and budget impact (BI) of introducing a FIT-based CRC screening program for the insured population of the Fundación Arturo López Pérez (FALP) Cancer Center. A Markov model was developed to assess the cost-effectiveness of the FIT screening program compared with no screening. Healthy beneficiaries aged 50–69 years were invited to undergo FIT every two years. Expected costs, life-years gained (LYG), and the incremental cost-effectiveness ratio (ICER) were estimated, along with the BI. Deterministic sensitivity analyses were performed, and co-payment scenarios involving out-of-pocket expenses were also explored. The FIT-based CRC screening program was cost-effective across all scenarios analyzed, and even in a co-payment scenario it was dominant over no screening. FIT adherence and FIT positivity rate had the greatest influence on cost-effectiveness outcomes. Although the ICER indicated a favorable cost-effectiveness profile, BI estimates for the base-case scenario highlighted the substantial financial burden of implementing the program. Co-payment scenarios markedly reduced BI, making the program more affordable. FIT-based CRC screening is a cost-effective strategy for the FALP-insured population. However, its significant budgetary impact may hinder implementation. Shared funding mechanisms could mitigate these financial barriers and enhance program feasibility.
Muñoz‐Montecinos et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: